Swiss National Bank lifted its position in FibroGen, Inc (NASDAQ:FGEN) by 20.0% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 99,100 shares of the biopharmaceutical company’s stock after purchasing an additional 16,500 shares during the period. Swiss National Bank owned about 0.14% of FibroGen worth $3,201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in FGEN. BlackRock Inc. increased its stake in shares of FibroGen by 29,724.1% in the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after purchasing an additional 4,439,882 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of FibroGen by 8.4% in the first quarter. Vanguard Group Inc. now owns 5,047,018 shares of the biopharmaceutical company’s stock worth $124,409,000 after purchasing an additional 392,778 shares in the last quarter. Bogle Investment Management L P DE increased its stake in shares of FibroGen by 215.8% in the first quarter. Bogle Investment Management L P DE now owns 329,371 shares of the biopharmaceutical company’s stock worth $8,118,000 after purchasing an additional 225,083 shares in the last quarter. Prudential Financial Inc. increased its stake in shares of FibroGen by 95.2% in the first quarter. Prudential Financial Inc. now owns 409,350 shares of the biopharmaceutical company’s stock worth $10,090,000 after purchasing an additional 199,670 shares in the last quarter. Finally, Boston Advisors LLC purchased a new stake in shares of FibroGen in the second quarter worth $5,653,000. 47.49% of the stock is owned by hedge funds and other institutional investors.

In other FibroGen news, insider K Peony Yu sold 5,000 shares of the company’s stock in a transaction on Monday, July 10th. The shares were sold at an average price of $32.98, for a total transaction of $164,900.00. Following the completion of the transaction, the insider now directly owns 216,507 shares in the company, valued at $7,140,400.86. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Pat Cotroneo sold 4,000 shares of the company’s stock in a transaction on Thursday, July 6th. The stock was sold at an average price of $34.00, for a total transaction of $136,000.00. Following the transaction, the vice president now owns 167,366 shares of the company’s stock, valued at $5,690,444. The disclosure for this sale can be found here. Insiders have sold 506,828 shares of company stock valued at $22,574,671 over the last 90 days. 14.90% of the stock is currently owned by company insiders.

FibroGen, Inc (NASDAQ:FGEN) opened at 51.95 on Thursday. The stock’s market capitalization is $3.70 billion. The company’s 50-day moving average is $44.39 and its 200 day moving average is $32.56. FibroGen, Inc has a 1-year low of $15.60 and a 1-year high of $54.05.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.01). The company had revenue of $29.00 million for the quarter, compared to analyst estimates of $34.80 million. FibroGen had a negative return on equity of 64.42% and a negative net margin of 105.59%. Equities analysts predict that FibroGen, Inc will post ($1.80) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/28/swiss-national-bank-has-3-20-million-stake-in-fibrogen-inc-fgen.html.

A number of analysts have recently issued reports on FGEN shares. Jefferies Group LLC reissued a “buy” rating and issued a $75.00 price objective on shares of FibroGen in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) cut shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 target price for the company. in a research note on Friday, July 21st. BidaskClub cut shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 target price on shares of FibroGen in a research note on Thursday, September 14th. Finally, Citigroup Inc. reaffirmed a “buy” rating and set a $48.00 target price on shares of FibroGen in a research note on Monday, June 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $60.17.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.